Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk

Next Previous
Trial Profile

A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omzotirome (Primary)
  • Indications Lipid metabolism disorders; Metabolic syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Torrent Pharmaceuticals

Most Recent Events

  • 25 Sep 2013 Primary endpoint (Efficacy in increasing insulin sensitivity of TRC150094 once daily dosing for 4 weeks in male patients with increased cardiometabolic risk), has not been met, according to results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
  • 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
  • 11 Mar 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2013-03-003470).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top